Name (Synonyms) | Correlation | |
---|---|---|
drug908 | Weekly Assessment Wiki | 0.71 |
drug516 | Monitoring Visit - Week 8 Wiki | 0.71 |
drug369 | Hydroxychloroquine - Daily dosing Wiki | 0.71 |
drug494 | Matched Placebo Hydroxychloroquine Wiki | 0.71 |
drug514 | Monitoring Visit - Baseline Wiki | 0.71 |
drug515 | Monitoring Visit - Week 4 Wiki | 0.71 |
drug368 | Hydroxychloroquine - Daily Dosing Wiki | 0.71 |
drug935 | blood samples Wiki | 0.71 |
drug627 | Placebo oral tablet Wiki | 0.16 |
Name (Synonyms) | Correlation | |
---|---|---|
D004660 | Encephalitis NIH | 0.71 |
D009410 | Nerve Degeneration NIH | 0.71 |
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Metro Detroit, Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.
Description: Plan statistical analyses will include the assumption that up 10% of HCW at risk will become infected if no prophylactic treatment is provided. Therefore we expect that HCQ treatment arm will provide a reduction in the number of SARS-CoV 2 infections by 30%, with an expected study retention rate of 90%, a sample size of ~1500 participants per group, will have an 80% power to detect the difference at p=0.05.
Measure: Reduction in the number of COVID-19 infections in healthcare workers. Time: 8 WeeksThe number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.
Description: Time taken for incidence of COVID-19 disease between Hydroxychloroquine and placebo arms
Measure: Time to positive COVID-19 disease Time: Assessed up to 90 daysDescription: Number of COVID-19 symptoms based on clinical guidelines and test positive infections per study arm
Measure: Number of COVID-19 test positive cases Time: Assessed up to 90 daysDescription: Number of test positive COVID-19 serological test positive cases per study arm
Measure: Number of COVID-19 serological test positive cases Time: Assessed up to 90 daysDescription: Severity based on hospitalisation
Measure: Severity of COVID-19 disease between each arm Time: Assessed up to 90 daysDescription: Number of common COVID-19 complications between arms
Measure: Number of common COVID-19 complications between each arm Time: Assessed up to 90 days